Skip to main content
. Author manuscript; available in PMC: 2014 Feb 1.
Published in final edited form as: Neuropharmacology. 2012 Sep 13;65:90–100. doi: 10.1016/j.neuropharm.2012.09.005

Table 2.

Body weight, adiposity and serum leptin levels with short-term leptin overexpression.

rAAV-Control rAAV-Leptin into VTA rAAV-Leptin into MBH
BW, g 332 ± 4a 304 ± 8c 294 ± 6b
Adiposity, g 83.6 ± 1.5a 65.0 ± 2.3b 61.6 ± 3.0b
WAT, g 6.9 ± 0.3a 3.7 ± 0.3b 3.4 ± 1.1b
Serum Leptin, ng/ml 3.3 ± 0.5a 1.4 ± 0.4b 1.3 ± 0.3c

Data represent the mean ± SE of 7-8 rats per group.

Adiposity was determined by TD-NMR prior to death at day 9.

WAT represents the sum of PWAT, RTWAT, and EWAT at death.

a

P<0.001 for difference with treatment at day 9 by one-way ANOVA.

b

P<0.01 for difference from control group by post-hoc analysis.

c

P<0.05 for difference from control group by post-hoc analysis.